Are Zinbryta and Lemtrada the Same Thing?
Because of their safety profiles, the use of Zinbryta and Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
Side effects of Zinbryta and Lemtrada that are similar include runny or stuffy nose, upper respiratory tract infection, skin rash (including drug rash), flu symptoms/influenza, mouth pain, sore throat, and fever.
Side effects of Lemtrada that are different from Zinbryta include headache, nausea, urinary tract infection (UTI), fatigue, insomnia, herpes viral infection, hives, itching, thyroid gland disorders, fungal infection, joint pain, pain in extremities, back pain, diarrhea, sinus infection, throat pain, numbness or tingling, dizziness, abdominal pain, flushing of the face/neck/chest, vomiting, cough, chills, changes in taste, skin swelling, indigestion, blood in the urine, shortness of breath, fast heartbeat, anxiety, weakness, and muscle pain.
Lemtrada may also interact with other drugs.
What Are Possible Side Effects of Zinbryta?
Common side effects of Zinbryta include:
- runny or stuffy nose
- upper respiratory tract infection
- rash, including drug rash
- skin rash
- mouth pain
- sore throat
- swollen lymph nodes
- increased alanine aminotransferase (ALT)
- anemia, and
Less common side effects of Zinbryta include:
- abnormal liver function test,
- decreased lymphocyte count
- dry skin
- skin redness
- hair bumps (folliculitis)
- increased liver enzymes
- enlarged lymph nodes
- skin peeling
- toxic skin eruption, and
- viral infection
What Are Possible Side Effects of Lemtrada?
Common side effects of Lemtrada include:
- runny nose,
- sore throat,
- nasal congestion,
- urinary tract infection,
- upper respiratory tract infection,
- herpes viral infection,
- thyroid gland disorders,
- fungal infection,
- joint pain,
- pain in extremity,
- back pain,
- sinus infection,
- mouth and throat pain,
- numbness or tingling, dizziness,
- abdominal pain,
- flushing of the face/neck/chest,
- changes in sense of taste,
- flu symptoms,
- skin swelling,
- blood in the urine,
- shortness of breath,
- fast heart beat,
- weakness, or
- muscle pain
What Is Zinbryta?
Zinbryta (daclizumab) injection is an interleukin-2 receptor blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
What Is Lemtrada?
Lemtrada (alemtuzumab) is a recombinant humanized IgG1 kappa monoclonal antibody used to treat patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
What Drugs Interact With Zinbryta?
Zinbryta may interact with hepatotoxic drugs or herbal products. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant before taking Zinbryta. It is unknown if it would affect a fetus. It is unknown if Zinbryta passes into breast milk or if it would affect a nursing infant. Consult your doctor before breastfeeding.
What Drugs Interact With Lemtrada?
Lemtrada may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Lemtrada should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
How Should Zinbryta Be Taken?
The recommended dosage of Zinbryta is 150 milligrams once monthly.
How Should Lemtrada Be Taken?
The recommended dosage of Lemtrada is 12 mg/day administered by intravenous infusion for 2 treatment courses: First Treatment Course: 12 mg/day on 5 consecutive days (60 mg total dose; Second Treatment Course: 12 mg/day on 3 consecutive days (36 mg total dose) administered 12 months after the first treatment course.
All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).
Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.
Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.
The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.
As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.
Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.
If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.
You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.
Sanofi. Lemtrada Product Information